Hematologic malignancy studies use similar categorical response criteria to classify continuous assessments of disease burden, such as percent blasts in Acute Myeloid Leukemia (AML) [99], BCRABL/BCR ratio in Chronic Myeloid Leukemia (CML) [100], and M-protein in multiple myeloma (MM) [101]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.